Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Intraocular Lymphoma × zanubrutinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 22 Leukemia, Lymphocytic, Chronic, B-Cell 17 Lymphoma, Mantle-Cell 15 Waldenstrom Macroglobulinemia 9 Lymphoma, Follicular 9 Lymphoma, B-Cell, Marginal Zone 7 Lymphoma 6 Recurrence 5 Lymphoma, Non-Hodgkin 4 Lymphoma, B-Cell 2 Neoplasms 1 Leukemia, B-Cell 1 Leukemia 1 Intraocular Lymphoma 1 Dendritic Cell Sarcoma, Interdigitating 1 Congenital Abnormalities 1

Interventions

Rituximab 8 Cyclophosphamide 7 Peripheral Blood Stem Cell Transplantation 6 Methotrexate 6 fludarabine phosphate 5 Dexamethasone 5 Whole-Body Irradiation 4 Tacrolimus 4 Mycophenolic Acid 4 Cytarabine 4 Cyclosporine 4 Radiotherapy 3 Filgrastim 3 pegfilgrastim 2 etoposide phosphate 2 Transplantation 2 Lenalidomide 2 Granulocyte Colony-Stimulating Factor 2 Etoposide 2 Carboplatin 2 Calcium Dobesilate 2 Busulfan 2 Antilymphocyte Serum 2 zanubrutinib 1 sodium thiosulfate 1 sargramostim 1 oblimersen 1 merphos 1 ibrutinib 1 Vorinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06973811 2025-05-20

ZR-MTX

Peking Union Medical College Hospital

Phase 2 Not yet recruiting

Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡